Core Viewpoint - Fuhong Hanlin (02696) shares rose over 5%, reaching a price of 68.7 HKD, with a trading volume of 34.25 million HKD, following the announcement of its PD-1 antibody drug, Surulitinib injection (H drug), being proposed for breakthrough therapy designation for use in combination with chemotherapy for gastric cancer [1] Group 1: Company Developments - The H drug is the first PD-1 monoclonal antibody approved for first-line treatment of small cell lung cancer globally [1] - On November 6 and November 10, Boyu Capital increased its holdings in Fuhong Hanlin by purchasing 262,500 shares and 80,000 shares of H shares, raising its stake from 5.84% to 7% [1] - Boyu Capital had previously invested 21.27 million HKD to increase its holdings from 4.89% to 5.15% on June 18, crossing the 5% threshold for mandatory disclosure [1]
复宏汉霖再涨超5% H药拟首次纳入突破性疗法 博裕资本继续增持公司股份